MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Acasti Pharma ROA Ratio 2011-2026 | ACST
Annual ROA Ratio Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.29 | -17.53 | -53.62 | -7.63 | -31.51 | - | -106.39 | -93.66 | -44.18 | -22.15 | -4.45 | -25.45 | -56.63 | -41.33 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.45 | -106.39 | -39.83 |
Quarterly ROA Ratio Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.39 | -19.8 | -23.64 | -15.79 | -18.93 | -15.28 | -14.22 | -12.83 | -16.16 | -16.35 | -16.24 | -11.03 | -14.33 | -14.31 | -15.17 | -13.4 | -24.03 | -31.35 | -49.69 | -64.42 | -84.84 | -74.21 | -50.93 | -127.11 | -213.39 | -213.39 | -106.69 | -106.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -11.03 | -213.39 | -50.02 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | $ 20.29 | -1.98 % | $ 2.56 B | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-26.55 | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.59 | -1.66 % | $ 1.4 B | Britain |
 |
Certara
CERT
|
-0.1 | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-59.34 | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-2.95 | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
27.51 | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
-268.92 | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
-37.95 | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Codexis
CDXS
|
-43.81 | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-385.68 | $ 27.88 | 1.79 % | $ 363 M | USA |
 |
Galecto
GLTO
|
-100.32 | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
22.5 | $ 27.66 | -6.71 % | $ 17.7 B | Danmark |
 |
Halozyme Therapeutics
HALO
|
12.55 | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
Hoth Therapeutics
HOTH
|
-106.17 | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
12.48 | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
-4.78 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-82.01 | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-31.82 | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immuron Limited
IMRN
|
-11.48 | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
1.73 | $ 10.09 | 1.0 % | $ 635 M | Germany |
 |
Immunic
IMUX
|
-404.01 | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
-53.31 | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
-78.39 | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
-56.34 | $ 0.8 | -2.44 % | $ 1.96 M | Canada |